Chapters

Transcript

Video

Why is down-titration from a high-intensity statin dose potentially problematic, and what are the pragmatic implications as they relate to PCSK9 inhibitor use in patients who cannot achieve optimal CV reduction with statin therapy?

Why is down-titration from a high-intensity statin dose potentially problematic, and what are the pragmatic implications as they relate to PCSK9 inhibitor use in patients who cannot achieve optimal CV reduction with statin therapy?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Robert Rosenson, MD

Robert Rosenson, MD

Professor of Medicine (Cardiology)
Mount Sinai Icahn School of Medicine
Director, Cardiometabolics Unit
Mount Sinai Heart Institute
New York, NY